Ran-Ran Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ran-Ran Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chengxian Guo
Central South University Third Xiangya Hospital Center of Clinical Pharmacology Changsha, Changsha, China
1 shared publication - Guoping Yang
Center of Clinical Pharmacology, The Third Xiangya Hospital, Central South University, Changsha, China
1 shared publication - Hong Yuan
Department of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, China
1 shared publication - Hongyi Tan
Department of Respiratory Medicine, Changsha Central Hospital, University of South China, Changsha, China
1 shared publication - Jiajie Zhu
Shenzhen University
1 shared publication - Jianwei Zhao
Shenzhen HUASUAN Technology Co., Ltd. , Shenzhen 518107
1 shared publication
Latest Publications
- 2 April 2025
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 162 (13)
MView: A pre- and post-processing tool for quantum chemistry calculation
A user-friendly graphical interface software named MView has been developed for molecular data processing. Featuring an intuitive graphical user interface design, MView enables analysis and visualization of quantum chemistry results, including molecular dimensions, thermochemical parameters, vibrational spectra (infrared/Raman), UV–Vis spectra, and automated generation of scan task input files. The software simplifies the workflow by directly analyzing output from mainstream computational packages (Gaussian, ORCA, DMol3, CP2K, xtb, etc.) and provides interfaces for visualization tools (Jmol, Avogadro, GaussView, VESTA, etc.) to facilitate one-click visualization of molecular structures.
- 2 April 2025
- Published by AIP Publishing in The Journal of Chemical Physics
- Vol. 162 (13)
MView: A pre- and post-processing tool for quantum chemistry calculation
A user-friendly graphical interface software named MView has been developed for molecular data processing. Featuring an intuitive graphical user interface design, MView enables analysis and visualization of quantum chemistry results, including molecular dimensions, thermochemical parameters, vibrational spectra (infrared/Raman), UV–Vis spectra, and automated generation of scan task input files. The software simplifies the workflow by directly analyzing output from mainstream computational packages (Gaussian, ORCA, DMol3, CP2K, xtb, etc.) and provides interfaces for visualization tools (Jmol, Avogadro, GaussView, VESTA, etc.) to facilitate one-click visualization of molecular structures.
- Open Access
- 20 October 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e109300
Evaluation of the Highly Variable Agomelatine Pharmacokinetics in Chinese Healthy Subjects to Support Bioequivalence Study
We aim to obtain the intra-subject coefficient of variability of a highly variable antidepressant agomelatine in humans, and propose an adjusted bioequivalence assessment strategy. A single-dose, randomized crossover design was conducted in four periods (reference administered thrice, placebo administered once) separated by seven days. A validated LC-MS/MS assay was used to measure drug concentrations in serial blood samples. The intra-subject coefficient of variability was calculated using the residual variance of ANOVA analysis, and the results for Cmax and AUC0-t was 78.34% and 43.52%, respectively, in Chinese healthy subjects. The sample size required for standard BE study were 124(192, 340) if the expected deviation between the reference and generic products was set to 0 (5%, 10%). Agomelatine meets the criteria for highly variable drug in Chinese healthy male subjects, and the traditional BE criteria for agomelatine needs to be adjusted to alleviate the resource and ethical burden of using a large numbers of subjects in clinical trials. Our clinical data on the intra-subject variability of agomelatine PK in Chinese healthy population enables to adjust bioequivalence (BE) assessment approach for agomelatine based on the RSABE approaches recommended by regulatory agencies. ChiCTR.org ChiCTR-TTRCC-13003835
- 20 October 2014
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (10) , e109300
Open AccessEvaluation of the Highly Variable Agomelatine Pharmacokinetics in Chinese Healthy Subjects to Support Bioequivalence Study
We aim to obtain the intra-subject coefficient of variability of a highly variable antidepressant agomelatine in humans, and propose an adjusted bioequivalence assessment strategy. A single-dose, randomized crossover design was conducted in four periods (reference administered thrice, placebo administered once) separated by seven days. A validated LC-MS/MS assay was used to measure drug concentrations in serial blood samples. The intra-subject coefficient of variability was calculated using the residual variance of ANOVA analysis, and the results for Cmax and AUC0-t was 78.34% and 43.52%, respectively, in Chinese healthy subjects. The sample size required for standard BE study were 124(192, 340) if the expected deviation between the reference and generic products was set to 0 (5%, 10%). Agomelatine meets the criteria for highly variable drug in Chinese healthy male subjects, and the traditional BE criteria for agomelatine needs to be adjusted to alleviate the resource and ethical burden of using a large numbers of subjects in clinical trials. Our clinical data on the intra-subject variability of agomelatine PK in Chinese healthy population enables to adjust bioequivalence (BE) assessment approach for agomelatine based on the RSABE approaches recommended by regulatory agencies. ChiCTR.org ChiCTR-TTRCC-13003835